Variant-Resistant SARS-CoV-2 Detection Through Redundant Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for detecting SARS-CoV-2 are susceptible to false negatives due to mutations and variants, failing to accurately detect the presence of the virus when mutations occur in its nucleic acid sequence, which can lead to misdiagnoses and hinder timely implementation of appropriate treatment and infection control measures.
Innovation Solution
The use of redundant assays targeting multiple regions of the SARS-CoV-2 genome, such as the Orf1a, Orf1b, and N genes, along with potential targeting of S, E, or M genes, ensures robust detection by compensating for mutations, utilizing multiple detection channels and redundant assays to increase the likelihood of detecting the virus even in the presence of variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single assay targeting a specific nucleic acid sequence is used, then the assay is simple and cost-effective, but it fails to detect variant sequences with mutations, leading to false negatives
Solution Approach 1:
The patent divides the detection task into multiple independent assays, each targeting a different region or aspect of the viral genome. Instead of relying on a single assay that may fail due to mutations, the method segments the detection into multiple parallel tests (e.g., targeting different genes or genomic regions), ensuring that at least one assay remains effective even if others fail due to variant mutations.
Solution Approach 2:
The patent creates a universal detection system that can handle both wild-type and variant sequences through a panel of assays with different specificities. Each assay in the panel serves multiple functions: detecting specific variants, detecting wild-type strains, and providing redundancy. This multi-functional approach allows a single detection platform to address diverse viral sequences without requiring separate specialized assays for each variant.
2Reliability
If multiple redundant assays are used to detect mutations and variants, then detection accuracy improves, but the complexity of the detection system increases
Solution Approach 1:
The patent merges multiple individual assays into an integrated detection panel that operates as a unified system. The assays are combined in a single detection platform with standardized protocols, reagents, and data interpretation guidelines. This merging reduces the operational complexity that would arise from running separate assays independently, while maintaining the reliability benefits of multiple redundant detection targets.
3Reliability
If multiple target regions are analyzed, then the likelihood of detecting variants increases, but the time required for detection and analysis increases
Solution Approach 1:
The patent implements continuous detection through parallel processing of multiple assays simultaneously. Rather than sequentially analyzing different target regions one after another, the method performs multiple assays in parallel, allowing all target regions to be analyzed at the same time. This continuous parallel action maintains detection robustness across multiple targets while minimizing the total time required, as all assays proceed concurrently rather than sequentially.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the accuracy of SARS-CoV-2 detection, reducing false negative rates and ensuring timely and effective implementation of treatment and control measures by maintaining assay efficacy despite genetic variations.
Implementation Method 1
genetic assays frequently utilize sequence-specific binding or hybridization between two or more nucleic acid molecules
Implementation Method 2
often with a subsequent step of nucleotide polymerization prior to detection
Data Source
AI summary
Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of SARS-CoV-2, including SARS-CoV-2 variants, or other coronaviruses from samples including veterinary samples, clinical samples, food samples, forensic sample, an environmental sample (e.g., soil, dirt, garbage, sewage, air, or water), including food processing and manufacturing surfaces, or a biological sample.